###begin article-title 0
Host PrP Glycosylation: A Major Factor Determining the Outcome of Prion Infection
###end article-title 0
###begin p 1
###xml 680 682 680 682 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 1215 1217 1215 1217 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 330 345 <span type="species:ncbi:10090">transgenic mice</span>
###xml 456 460 <span type="species:ncbi:10090">mice</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
###xml 733 737 <span type="species:ncbi:10090">mice</span>
The expression of the prion protein (PrP) is essential for transmissible spongiform encephalopathy (TSE) or prion diseases to occur, but the underlying mechanism of infection remains unresolved. To address the hypothesis that glycosylation of host PrP is a major factor influencing TSE infection, we have inoculated gene-targeted transgenic mice that have restricted N-linked glycosylation of PrP with three TSE strains. We have uniquely demonstrated that mice expressing only unglycosylated PrP can sustain a TSE infection, despite altered cellular location of the host PrP. Moreover we have shown that brain material from mice infected with TSE that have only unglycosylated PrPSc is capable of transmitting infection to wild-type mice, demonstrating that glycosylation of PrP is not essential for establishing infection within a host or for transmitting TSE infectivity to a new host. We have further dissected the requirement of each glycosylation site and have shown that different TSE strains have dramatically different requirements for each of the glycosylation sites of host PrP, and moreover, we have shown that the host PrP has a major role in determining the glycosylation state of de novo generated PrPSc.
###end p 1
###begin title 2
Author Summary
###end title 2
###begin title 3

###end title 3
###begin p 4
###xml 429 435 <span type="species:ncbi:10090">murine</span>
###xml 642 646 <span type="species:ncbi:10090">mice</span>
###xml 828 832 <span type="species:ncbi:10090">mice</span>
In prion infection, disease requires the presence of the endogenous host-encoded prion protein, PrP. PrP is a glycoprotein (modified by the addition of sugar molecules) with two consensus sites for sugars to attach. Different PrP forms are usually observed: one diglycosylated, two different monoglycosylated, and one unglycosylated. How PrP glycosylation influences prion infection remains obscure. We have used three different murine transgenic models, developed with the gene-replacement technique, to investigate each glycotype of PrP contribution to prion diseases, or transmissible spongiform encephalopathies (TSEs). For this purpose, mice expressing mono- or unglycosylated PrP were challenged with different prion strains. Remarkably, we found that glycosylation of host PrP is not mandatory for TSE infection, because mice expressing only unglycosylated PrP were susceptible to infection and able to transmit the disease to other animals. However, we also show that host PrP glycosylation can modulate the infectious process, since strains differ in their ability to infect hosts with restricted PrP glycosylation. These results elucidate the role of glycosylation in prion infection and in particular demonstrate that strains need sugars at specific sites of host PrP to successfully induce prion disease.
###end p 4
###begin p 5
The primary determinant of the prion infectious process is the glycosylation status of the host prion protein, PrP.
###end p 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 350 351 350 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 402 403 402 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b001">1</xref>
###xml 471 473 471 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 511 512 511 512 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 642 643 642 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 650 652 650 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 654 655 654 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b002">2</xref>
###xml 665 667 665 667 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 987 988 987 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b003">3</xref>
###xml 989 990 989 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b006">6</xref>
###xml 130 135 <span type="species:ncbi:9940">sheep</span>
###xml 137 143 <span type="species:ncbi:9913">bovine</span>
###xml 179 185 <span type="species:ncbi:9913">cattle</span>
###xml 272 278 <span type="species:ncbi:9606">humans</span>
Transmissible spongiform encephalopathies (TSEs), or prion diseases, are fatal neurodegenerative diseases that include scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle, chronic wasting disease (CWD) in deer and elk and Creutzfeldt-Jakob disease (CJD) in humans. The host-encoded glycophosphatidylinositol anchored prion protein, PrPC, is essential for the development of TSE disease [1], and a common feature of these diseases is the accumulation of PrPSc in the brain, an abnormal form of PrPC, which displays partial resistance to proteinase K (PK) digestion. This accumulation is considered to arise via conversion of PrPC to PrPSc [2], and PrPSc has been proposed to be the infectious agent. If this is indeed the case, it is not clear how a protein alone can encipher TSE strain information resulting in different incubation times and targeting of pathological lesions in the brain, but it has been suggested that differences in glycosylation and/or conformation [3-6] of PrP could account for these different properties.
###end p 7
###begin p 8
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b007">7</xref>
###xml 269 270 269 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b008">8</xref>
###xml 415 416 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b006">6</xref>
###xml 512 514 512 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 570 572 570 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 645 646 645 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b009">9</xref>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b010">10</xref>
###xml 711 713 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b011">11</xref>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b012">12</xref>
###xml 1044 1059 <span type="species:ncbi:10090">transgenic mice</span>
PrP has two potential sites for N-linked glycosylation, which are variably occupied, producing di-, mono-, and unglycosylated PrP [7]. The diversity in glycosylation, combined with the complexity of added sugars, results in a large number of glycosylated forms of PrP [8]. These different glycoforms of host PrP have been proposed as a mechanism to determine the targeting of TSE strains to specific brain regions [6]. Moreover, PrP glycoform analysis in the infected host (ratios of di- and monoglycosylated PrPSc, as well as the relative mobility of unglycosylated PrPSc) is increasingly used as a means of distinguishing between TSE strains [9,10] and for identifying and classifying newly emerging strains [11,12]. However, the significance of different glycosylated forms of PrP in the normal function of PrP as well as the disease process is not understood. To investigate the involvement of host PrP glycosylation on TSE disease susceptibility and pathology following infection with different TSE strains, we have used our gene-targeted transgenic mice with restricted host PrP glycosylation and inoculated them intracerebrally with three TSE strains.
###end p 8
###begin p 9
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b013">13</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b014">14</xref>
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 184 189 <span type="species:ncbi:10090">mouse</span>
###xml 445 449 <span type="species:ncbi:10090">mice</span>
Three inbred lines of gene-targeted mice, carrying mutations at the first, second, or both PrP N-linked glycosylation sites-referred to as G1 (N180T), G2 (N196T), and G3 (N180T-N196T) mouse lines, respectively [13]-were used in these experiments. The gene targeting approach ensures that the altered PrP allele remains in the correct genomic location under control of the endogenous promoter [14]. Importantly, this approach allows each line of mice to be compared, and thus the effect of the loss of each glycosylation site on disease pathogenesis can be analysed directly.
###end p 9
###begin p 10
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b013">13</xref>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b013">13</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b013">13</xref>
###xml 830 832 830 832 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
###xml 200 204 <span type="species:ncbi:10090">mice</span>
###xml 273 277 <span type="species:ncbi:10090">mice</span>
###xml 311 315 <span type="species:ncbi:10090">mice</span>
###xml 609 613 <span type="species:ncbi:10090">mice</span>
Western blot analysis has demonstrated that both G1 and G2 lines lack diglycosylated, but express mono- and unglycosylated PrP, whereas G3 mice only express unglycosylated PrP [13]. PrP in the mutant mice has been shown to have a similar cellular localisation in G1 and G2 mice to that of wild type, whereas G3 mice, which lack all PrP N-linked carbohydrates, have been demonstrated to have mainly intracellular PrP [13]. Despite differences in intracellular localisation, mono- and unglycosylated PrP levels in the brain are similar to those in wild type [13]. Here we establish, using these unique lines of mice, that although host PrP glycosylation is not essential to support TSE disease, it can have a profound effect on capacity of TSE strains to infect the host. Furthermore we demonstrate in vivo that glycosylation of PrPSc is not essential for TSE strain to transmit infectivity.
###end p 10
###begin title 11
Results
###end title 11
###begin p 12
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b015">15</xref>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
Three homozygous lines (G1/G1, G2/G2, and G3/G3, subsequently referred to as G1, G2, and G3 respectively), together with 129/Ola wild-type mice (which acted as controls, because the gene-targeted mice are inbred lines on a 129/Ola background), were infected intracerebrally (i.c.) with the TSE strains 79A and ME7, which are classified as low and medium glycosylated strains, respectively, according to their glycoform analysis based upon the ratio of the diglycosyl and monoglycosyl bands by Western blotting [15]. Each of these lines of mice was shown to respond in strikingly different ways to infection with each TSE strain.
###end p 12
###begin title 13
###xml 3 7 <span type="species:ncbi:10090">Mice</span>
G3 Mice Expressing Unglycosylated PrP Differ in Their Response to Various TSE Strains
###end title 13
###begin p 14
###xml 134 141 134 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060100-t001">Table 1</xref>
###xml 453 461 449 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g001">Figure 1</xref>
###xml 685 693 681 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g002">Figure 2</xref>
###xml 699 700 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g002">2</xref>
###xml 3 7 <span type="species:ncbi:10090">mice</span>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 314 318 <span type="species:ncbi:10090">mice</span>
###xml 799 814 <span type="species:ncbi:10090">transgenic mice</span>
G3 mice were susceptible to 79A infection, with clinical TSE and spongiform degeneration of the brain being observed in 4/21 animals (Table 1). However, although only four mice presented with clinical TSE disease, with considerably longer and wider range of incubation times (435 +/- 92 d) compared with wild-type mice (148 +/- 2.6 d), Western blot analysis of six brains all demonstrated PK-resistant PrP, whether or not clinical disease was observed (Figure 1A). Furthermore, immunohistochemical analysis of brains revealed variation in the amount of PrP immunopositivity amongst cases with some animals without clinical signs showing widespread accumulation of PrP in the cerebrum (Figure 2A and 2B), suggesting that a subclinical disease was also present in the G3 animals. Thus, 79A can infect transgenic mice in the absence of glycosylated host PrP, but this lack of glycosylation dramatically lengthens the incubation time of disease suggesting that glycosylation of host PrP facilitates infection by 79A.
###end p 14
###begin p 15
###xml 57 61 <span type="species:ncbi:10090">Mice</span>
Incubation Periods of Wild-Type and Glycosylation Mutant Mice Infected with TSE Strains
###end p 15
###begin title 16
###xml 73 77 <span type="species:ncbi:10090">Mice</span>
Western Blot Analysis of Brains from TSE Inoculated Glycosylation Mutant Mice
###end title 16
###begin p 17
Brain homogenates were treated with or without PK as indicated prior to SDS PAGE analysis.
###end p 17
###begin p 18
###xml 79 83 <span type="species:ncbi:10090">mice</span>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
(A) G3 and wild-type animals inoculated with 79A. Lanes 1-2: 129/Ola wild-type mice clinically (clin) positive/pathologically (path) positive; lanes 3-4: G3 mice clin positive/path positive; lanes 5-6: G3 mice clin negative/path positive.
###end p 18
###begin p 19
###xml 69 73 <span type="species:ncbi:10090">mice</span>
###xml 117 121 <span type="species:ncbi:10090">mice</span>
###xml 181 185 <span type="species:ncbi:10090">mice</span>
(B) G3 and wild-type animals inoculated with ME7. Lanes 1-2: 129/Ola mice clin positive/path positive; lanes 3-4: G3 mice clin negative/path negative with no plaques; lanes 5-6: G3 mice clin negative/path negative with plaques.
###end p 19
###begin p 20
###xml 84 88 <span type="species:ncbi:10090">mice</span>
(C) G2 and wild-type animals inoculated with ME7. Lanes 1-2: 129/Ola; lanes 3-6: G2 mice, brains positive for plaques. All animals clin positive/path positive.
###end p 20
###begin p 21
###xml 69 73 <span type="species:ncbi:10090">mice</span>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
(D) G2 and wild-type animals inoculated with 79A. Lanes 1-2: 129/Ola mice; lanes 3-6: G2 mice. All animals clin positive/path positive.
###end p 21
###begin p 22
###xml 70 74 <span type="species:ncbi:10090">mice</span>
###xml 90 94 <span type="species:ncbi:10090">mice</span>
(E) G2 and wild-type animals inoculated with 301C. Lanes 1-2: 129/Ola mice; lanes 3-6: G2 mice brains positive for plaques. All animals clin positive/path positive.
###end p 22
###begin p 23
###xml 69 73 <span type="species:ncbi:10090">mice</span>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
(F) G1 and wild-type animals inoculated with 79A. Lanes 1-2: 129/Ola mice; lanes 3-6: G1 mice. All animals clin positive/path positive. Lanes 1-4: 3-min exposure; lanes 5-6: 10-min exposure.
###end p 23
###begin p 24
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
Molecular weight markers indicated in KDa. Wild-type (Wt) mice are 129/Ola mice. Monoclonal antibody 7A12 (kindly provided by M.-S. Sy) was used for immunodetection of PrP.
###end p 24
###begin title 25
###xml 46 50 <span type="species:ncbi:10090">Mice</span>
Immunohistochemical Analysis of Brain from G3 Mice Inoculated with TSE Strains 79A or ME7
###end title 25
###begin p 26
Sections from the cerebrum and cerebellum were immunostained for PrP with monoclonal antibody 6H4 and analysed by light microscopy using a Nikon Eclipse E 800 microscope.
###end p 26
###begin p 27
###xml 84 88 <span type="species:ncbi:10090">mice</span>
Brain sections obtained from (A) clinically negative, or (B) clinically positive G3 mice after inoculation with 79A showing widespread accumulation of PrP in the hippocampus and thalamus are shown.
###end p 27
###begin p 28
###xml 53 57 <span type="species:ncbi:10090">mice</span>
(C and D) Brain sections from clinically negative G3 mice inoculated with ME7 showing large PrP positive plaques in subcallosal areas.
###end p 28
###begin p 29
###xml 55 59 <span type="species:ncbi:10090">mice</span>
(E and F) Brain section of clinically positive 129/Ola mice infected with 79A (E) or ME7 (F), showing widespread PrP deposition in the hippocampus and thalamus.
###end p 29
###begin p 30
###xml 103 108 <span type="species:ncbi:10090">mouse</span>
(G) Thioflavin-S fluorescent PrP-amyloid plaques in the subcallosal region of a clinically negative G3 mouse inoculated with 79A.
###end p 30
###begin p 31
###xml 74 79 <span type="species:ncbi:10090">mouse</span>
(H) Thioflavin-S treatment of sections from a clinically positive 129/Ola mouse infected with 79A with no presence of plaques.
###end p 31
###begin p 32
###xml 77 82 <span type="species:ncbi:10090">mouse</span>
(I) Thioflavin-S fluorescent PrP-amyloid plaques in a clinically negative G3 mouse infected with ME7.
###end p 32
###begin p 33
###xml 59 64 <span type="species:ncbi:10090">mouse</span>
(J) Thioflavin-S staining of a clinically positive 129/Ola mouse infected with ME7 with no presence of plaques.
###end p 33
###begin p 34
Magnifications: (A), (B), (E), and (F): 4x, (C), (G), (H), and (I): 10x; and (D): 40x .
###end p 34
###begin p 35
###xml 630 637 630 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060100-t002">Table 2</xref>
###xml 1073 1075 1067 1069 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 1127 1129 1121 1123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 1224 1226 1218 1220 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 175 180 <span type="species:ncbi:10090">mouse</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
###xml 446 451 <span type="species:ncbi:10090">mouse</span>
###xml 511 515 <span type="species:ncbi:10090">mice</span>
###xml 556 560 <span type="species:ncbi:10090">mice</span>
###xml 585 590 <span type="species:ncbi:10090">mouse</span>
###xml 1001 1006 <span type="species:ncbi:10090">mouse</span>
###xml 1151 1156 <span type="species:ncbi:10090">mouse</span>
To establish whether the brains of G3 79A-inoculated mice carried infectivity, brain homogenates from one clinically positive (incubation period 456 d) and one subclinical G3 mouse (incubation period 722 d; i.e. clinically negative but positive by immunohistochemistry and showing spongiform degeneration of the brain) were used to inoculate wild-type mice i.c.. For comparison, brain homogenate from a 79A inoculated wild-type (129/Ola) control mouse was also used to i.c. inoculate another group of wild-type mice. The brain extracts from the two 79A/G3 mice and the one 79A/129/Ola mouse were found to contain TSE infectivity (Table 2). The clinically positive 79A/G3 brain homogenate resulted in an incubation period of 197 d (+/-7.6), whereas the clinically negative 79A/G3 brain generated a shorter incubation time (164 +/- 2.2 d), but both G3 brain homogenates produced slightly longer incubation periods that that resulting from 79A/129/Ola (137 +/- 1.1 d). Western blot analysis of recipient mouse brains revealed the presence of di-, mono-, and unglycosylated PrPSc despite the absence of di- and monoglycosylated PrPSc in 79A inoculated G3 mouse brain (unpublished data). These data indicate that glycosylated PrPSc is not a prerequisite for the transmission of infectivity.
###end p 35
###begin p 36
###xml 28 33 <span type="species:ncbi:10090">Mouse</span>
###xml 91 95 <span type="species:ncbi:10090">Mice</span>
Second Passage of G2 and G3 Mouse Brain Inoculated with 79A; Incubation Periods of 129/Ola Mice
###end p 36
###begin p 37
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b016">16</xref>
###xml 298 306 298 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g001">Figure 1</xref>
###xml 339 346 339 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060100-t001">Table 1</xref>
###xml 592 600 592 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g002">Figure 2</xref>
###xml 606 607 606 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g002">2</xref>
###xml 702 710 702 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g002">Figure 2</xref>
###xml 741 749 741 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g002">Figure 2</xref>
###xml 1149 1151 1149 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b013">13</xref>
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 735 739 <span type="species:ncbi:10090">mice</span>
###xml 885 889 <span type="species:ncbi:10090">mice</span>
###xml 922 926 <span type="species:ncbi:10090">mice</span>
###xml 1219 1223 <span type="species:ncbi:10090">mice</span>
###xml 1277 1281 <span type="species:ncbi:10090">mice</span>
In contrast, G3 mice inoculated with ME7 did not show clinical signs of TSE disease or spongiform degeneration in the brain as determined by lesion profiling and were thus scored as pathologically negative [16]. Brains from selected animals analysed by Western blotting showed no PK-resistant PrP (Figure 1B) up to 740 d post inoculation (Table 1). Despite the lack of these indicators of TSE disease, brains of a number of animals showed PrP-positive plaques in the vicinity of the corpus callosum and, in one case, adjacent to the lateral ventricle; diffuse PrP deposits were not detected (Figure 2C and 2D). Thioflavin-S-treated brain sections confirmed the presence of PrP amyloid plaques in 79A- (Figure 2G) and ME7-inoculated G3 mice (Figure 2I). To determine whether the presence of the PrP amyloid plaques was in response to TSE inoculation rather than an innate ability of G3 mice to form plaques, age-matched G3 mice (24 animals in total) that were injected with brain homogenates from wild-type controls were examined but found to have no PrP accumulation in the brain (unpublished data). In addition, in agreement with previous studies [13], PrP accumulation was not observed in older (600 d) uninjected G3 mice. Therefore, the PrP accumulation in the brain of the mice inoculated with 79A and ME7 was clearly in response to inoculation with a TSE agent rather than due to any effect of the mutation in host PrP per se. Whether this PrP accumulation is associated with infectivity requires further subpassage of G3/ME7 brains; however, tissue was not available from this experiment to carry out this subpassage and therefore will be examined in future studies.
###end p 37
###begin title 38
###xml 3 7 <span type="species:ncbi:10090">Mice</span>
G2 Mice Differ in Their Response to Scrapie or BSE-Derived Strains
###end title 38
###begin p 39
###xml 223 230 219 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060100-t001">Table 1</xref>
###xml 401 409 397 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g003">Figure 3</xref>
###xml 533 541 529 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g004">Figure 4</xref>
###xml 573 575 569 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 692 694 688 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 741 749 737 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g001">Figure 1</xref>
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 31 35 <span type="species:ncbi:10090">mice</span>
###xml 303 308 <span type="species:ncbi:10090">mouse</span>
###xml 344 348 <span type="species:ncbi:10090">mice</span>
###xml 645 649 <span type="species:ncbi:10090">mice</span>
###xml 735 739 <span type="species:ncbi:10090">mice</span>
In contrast to G3 mice, all G2 mice were found to develop clinical signs of disease when inoculated with ME7 and presented with similar incubation periods to wild-type controls (160 +/- 2.5 d and 163 +/-2 d, respectively) (Table 1). Spongiform degeneration, determined by lesion profile analysis, of G2 mouse brains was comparable to wild-type mice both in the distribution and degree of vacuolation (Figure 3A). Wide spread, fine punctuate, coarse, and plaque-like PrP immunopositive deposits were detected in ME7-infected animals (Figure 4A). Mono- and unglycosylated PrPSc was detected by Western blot analysis in brains of ME7-inoculated G2 mice, whereas di-, mono- and unglycosylated PrPSc was detectable in wild-type, inoculated mice (Figure 1C).
###end p 39
###begin title 40
###xml 67 71 <span type="species:ncbi:10090">Mice</span>
Lesion Profile Analysis of TSE-Inoculated PrP Glycosylation Mutant Mice
###end title 40
###begin p 41
###xml 15 19 <span type="species:ncbi:10090">mice</span>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 204 208 <span type="species:ncbi:10090">mice</span>
G2 and 129/Ola mice were inoculated i.c. with TSE strains ME7 (A), 79A (B), or 301C (C) and G1 mice were inoculated i.c. with 79A (D). Squares: wild type; open triangles: G2; and solid triangles: G1. All mice (12 in each group) used in these analyses were clinically and pathologically positive.
###end p 41
###begin p 42
###xml 302 303 302 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 380 381 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 491 495 <span type="species:ncbi:10090">mice</span>
###xml 747 751 <span type="species:ncbi:10090">mice</span>
Nine gray matter areas: 1, dorsal medulla; 2, cerebellar cortex; 3, superior colliculus; 4, hypothalamus; 5, medial thalamus; 6, hippocampus; 7, septum; 8, cerebral cortex; 9, forebrain cortex and three white matter areas: 1*, cerebellar white matter; 2*, mesencephalic tegmentum; 3*, pyramidal tract (x-axis) were scored on scales of 0-5 for gray and 0-3 for white matter areas (y-axis). The mean scores for each area are shown (error bars +/- SEM). No differences between wild-type and G2 mice were observed after inoculation with ME7 (A) or 79A (B); however some differences in the superior colliculus and white matter areas were observed between the two groups when inoculated with 301C (C). Differences were observed between wild-type and G1 mice inoculated with 79A (D) especially in area: 2, 4, 8, and in the white matter.
###end p 42
###begin title 43
###xml 46 50 <span type="species:ncbi:10090">Mice</span>
Immunohistochemical Analysis of Brain from G2 Mice Inoculated with TSE Strains ME7, 79A, and 301C
###end title 43
###begin p 44
###xml 180 184 <span type="species:ncbi:10090">mice</span>
###xml 286 290 <span type="species:ncbi:10090">mice</span>
Brain sections were immunostained for PrP using monoclonal antibody 6H4 and analysed by light microscopy using a Nikon Eclipse E 800 microscope. Brains from clinically positive G2 mice inoculated with (A) ME7 or (B) 79A showing wide spread PrP deposition. Brains from 129/Ola wild-type mice inoculated with (C) ME7 or (D) 79A also showing wide spread PrP deposition.
###end p 44
###begin p 45
###xml 55 59 <span type="species:ncbi:10090">mice</span>
###xml 181 185 <span type="species:ncbi:10090">mice</span>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
The TSE strain 301C was used to inoculate (E and F) G2 mice, which showed wide spread plaque-like and fine punctuate PrP deposits in the cerebrum and cerebellum or (G and H) 129Ola mice, which also showed plaque-like PrP deposition. All 301C inoculated brains shown were from clinically positive mice.
###end p 45
###begin p 46
Magnifications: (A-E) and (G), 4x; (F) and (H), 10x.
###end p 46
###begin p 47
###xml 279 286 275 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060100-t001">Table 1</xref>
###xml 383 391 379 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g003">Figure 3</xref>
###xml 560 568 556 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g004">Figure 4</xref>
###xml 626 628 622 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 721 723 717 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 770 778 766 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g001">Figure 1</xref>
###xml 899 901 895 897 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 1280 1287 1270 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060100-t002">Table 2</xref>
###xml 1407 1409 1397 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b016">16</xref>
###xml 1527 1529 1517 1519 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 1604 1606 1594 1596 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 1608 1616 1598 1606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g005">Figure 5</xref>
###xml 1684 1686 1674 1676 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 1688 1696 1678 1686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g005">Figure 5</xref>
###xml 3 7 <span type="species:ncbi:10090">mice</span>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 319 324 <span type="species:ncbi:10090">mouse</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
###xml 454 459 <span type="species:ncbi:10090">mouse</span>
###xml 673 677 <span type="species:ncbi:10090">mice</span>
###xml 764 768 <span type="species:ncbi:10090">mice</span>
###xml 835 839 <span type="species:ncbi:10090">mice</span>
###xml 913 917 <span type="species:ncbi:10090">mice</span>
###xml 1001 1005 <span type="species:ncbi:10090">mice</span>
###xml 1011 1015 <span type="species:ncbi:10090">mice</span>
###xml 1547 1552 <span type="species:ncbi:10090">mouse</span>
G2 mice were also shown to be susceptible to TSE disease when inoculated with 79A, but whereas the incubation time with ME7 was similar to that in wild-type mice, with 79A, incubation time was significantly prolonged (167 +/- 9.3 d for G2/79A and 148 +/- 2.6 d for 79A/129/Ola) (Table 1). Spongiform degeneration of G2 mouse brains was also found to be comparable to wild-type mice (Figure 3B). Immunohistochemical analysis of selected 79A-inoculated G2 mouse brains revealed variable amounts of fine punctuate and plaque-like PrP depositions in the cerebrum (Figure 4B). By Western blot analysis, mono- and unglycosylated PrPSc was detected in brains of 79A-inoculated G2 mice, whereas di-, mono-, and unglycosylated PrPSc was detectable in wild-type, inoculated mice (Figure 1D). To determine whether the brains of 79A-inoculated G2 mice had TSE infectivity, despite the lack of diglycosylated PrPSc, wild-type mice were inoculated with brain homogenate from 79A-inoculated G2 and wild-type control mice. All mice were found to be susceptible to TSE disease with two independent 79A/G2 brain homogenates producing incubation times of 150 d (+/-3.4) and 159 d (+/-1.2) compared to 79A/129/Ola brain homogenate resulting in a slightly shorter incubation period of 140 d (+/-1.9) (Table 2). The pattern and degree of spongiform degeneration in all subpassage cases, as determined by lesion profile analysis [16], were found to be comparable (unpublished data). Western blot analysis revealed the glycosylation pattern of the PrPSc in the recipient mouse brain to possess di-, mono-, and unglycosylated PrPSc (Figure 5B) despite the inoculum possessing only mono- and unglycosylated PrPSc (Figure 5A).
###end p 47
###begin title 48
###xml 85 89 <span type="species:ncbi:10090">Mice</span>
Western Blot Analysis of Brains from Second Passage of 79A-Infected G2 and Wild-Type Mice
###end title 48
###begin p 49
###xml 112 116 <span type="species:ncbi:10090">mice</span>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
Brain homogenates from (A) clinically and pathologically positive 79A inoculated G2 or wild-type, 129/Ola (Wt), mice were used to i.c. inoculate 129/Ola mice.
###end p 49
###begin p 50
###xml 64 66 64 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 175 177 175 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 26 31 <span type="species:ncbi:10090">mouse</span>
###xml 84 88 <span type="species:ncbi:10090">mice</span>
(B) The 79A inoculated G2 mouse brains lacked diglycosylated PrPSc, but all 129/Ola mice inoculated with 79A/G2 or 79A/Wt brain material had di-, mono-, and unglycosylated PrPSc.
###end p 50
###begin p 51
###xml 21 26 <span type="species:ncbi:10090">mouse</span>
(C) Brain of a C57Bl mouse infected with 79A used as comparison for the glycotype.
###end p 51
###begin p 52
###xml 112 116 <span type="species:ncbi:10090">mice</span>
###xml 164 168 <span type="species:ncbi:10090">mice</span>
Brain homogenates from (D) clinically and pathologically positive ME7 inoculated-G2 or wild-type, 129/Ola (Wt), mice were used to intracerebrally inoculate 129/Ola mice.
###end p 52
###begin p 53
###xml 64 66 64 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 174 176 174 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 26 31 <span type="species:ncbi:10090">mouse</span>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
(E) The ME7 inoculated G2 mouse brains lacked diglycosylated PrPSc but all 129/Ola mice inoculated with ME7/G2 or ME7/Wt brain material had di-, mono-, and unglycosylated PrPSc.
###end p 53
###begin p 54
###xml 21 26 <span type="species:ncbi:10090">mouse</span>
(F) Brain of a C57Bl mouse infected with ME7 used as comparison for the glycotype.
###end p 54
###begin p 55
###xml 34 39 <span type="species:ncbi:10090">mouse</span>
Lanes 1-6: TSE-inoculated 129/Ola mouse brain. All samples were PK treated.
###end p 55
###begin p 56
###xml 305 313 305 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g005">Figure 5</xref>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
Moreover, the glycosylation pattern of the original Wt/79A inoculum was not changed after passage through G2 mice. The comparison of the electrophoretic mobility of the 79A in wild-type animals before and after passage through G2 mice revealed the same glycotype with a predominant monoglycosylated band (Figure 5C).
###end p 56
###begin p 57
###xml 227 229 227 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 327 329 327 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 331 339 331 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g005">Figure 5</xref>
###xml 345 346 345 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g005">5</xref>
###xml 475 483 475 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g005">Figure 5</xref>
###xml 557 559 557 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 657 659 657 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
###xml 260 264 <span type="species:ncbi:10090">mice</span>
###xml 469 473 <span type="species:ncbi:10090">mice</span>
To investigate this effect with another strain of agent, subpassage was performed from clinical positive G2/ME7 brains into wild-type animals. Western blot analysis of recipient wild-type mice also showed fully glycosylated PrPSc in the brain of the recipient mice, despite the inoculum having only mono- and unglycosylated PrPSc (Figure 5D and 5E). Furthermore, similarly to the 79A strain, the original Wt/ME7 glycosylation pattern was maintained after passage in G2 mice (Figure 5F). Therefore, it is clear that the ability to generate diglycosylated PrPSc in response to TSE infection does not depend on the presence of the diglycosylated species of PrPSc in the infecting inoculum.
###end p 57
###begin p 58
###xml 189 191 189 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 307 308 307 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b004">4</xref>
###xml 817 819 817 819 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 821 823 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b015">15</xref>
###xml 1165 1173 1161 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g003">Figure 3</xref>
###xml 1318 1326 1314 1322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g004">Figure 4</xref>
###xml 1332 1333 1328 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g004">4</xref>
###xml 1369 1371 1365 1367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 1402 1410 1398 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g001">Figure 1</xref>
###xml 1837 1838 1833 1834 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
###xml 353 357 <span type="species:ncbi:10090">mice</span>
###xml 438 442 <span type="species:ncbi:10090">mice</span>
###xml 512 516 <span type="species:ncbi:10090">mice</span>
###xml 687 691 <span type="species:ncbi:10090">mice</span>
###xml 706 710 <span type="species:ncbi:10090">mice</span>
###xml 740 745 <span type="species:ncbi:10090">mouse</span>
###xml 926 930 <span type="species:ncbi:10090">mice</span>
###xml 969 973 <span type="species:ncbi:10090">mice</span>
###xml 1064 1068 <span type="species:ncbi:10090">mice</span>
###xml 1159 1163 <span type="species:ncbi:10090">mice</span>
###xml 1281 1285 <span type="species:ncbi:10090">mice</span>
###xml 1815 1819 <span type="species:ncbi:10090">mice</span>
We originally chose the 79A and ME7 strains of TSE for use in this study, because glycoform ratio analysis had revealed them to have a different predominance of mono- and diglycosylated PrPSc; with 79A predominantly monoglycosylated, whereas ME7 was more equally di- and monoglycosylated in wild-type mice [4]. Since the disease profiles observed in G2 mice that were infected with ME7 and 79A were similar to those observed in wild-type mice, with the exception of slightly prolonged incubation times in G2/79A mice, we decided to analyse the effect of the second glycosylation site of PrP with a further TSE strain having a different glycoform ratio. For this purpose we inoculated G2 mice and wild-type mice intracerebrally with the BSE mouse-adapted TSE strain 301C, which has a predominance of diglycosylated PrPSc [15]. In contrast to ME7 and 79A, a very prolonged incubation time was observed in the 301C inoculated G2 mice (354 +/- 5.3 d) compared to wild-type mice (166 +/- 1.5 d). However, despite the prolonged incubation time in the 301C-inoculated G2 mice, the overall pattern of spongiform degeneration was similar to that observed in wild-type mice (Figure 3C). Analysis by immunohistochemistry showed wide spread, plaque-like, and fine punctuate PrP deposits in G2 mice in the cerebrum and cerebellum (Figure 4E and 4F), and mono- and unglycosylated PrPSc was detected by Western blot (Figure 1E). These experiments clearly show that this BSE-derived strain does not require diglycosylated host PrP (the predominant characteristic of the glycoform used to identify BSE strains) to be pathogenic; however, the presence of sugars at N196 of host PrP would appear to allow more efficient progression of TSE disease, because the time taken to reach terminal disease is dramatically shorter in wild-type mice having normal PrPC glycosylation. The importance of the presence of glycans at N196 for efficient TSE disease progression is therefore clearly TSE strain dependent.
###end p 58
###begin title 59
###xml 3 7 <span type="species:ncbi:10090">Mice</span>
G1 Mice Are Susceptible to 79A, but Are Resistant to ME7, Strain Infection
###end title 59
###begin p 60
###xml 537 544 537 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060100-t001">Table 1</xref>
###xml 623 631 623 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g003">Figure 3</xref>
###xml 717 719 717 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 766 768 766 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 802 810 802 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g001">Figure 1</xref>
###xml 911 919 911 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g006">Figure 6</xref>
###xml 922 923 922 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g006">6</xref>
###xml 930 931 930 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g006">6</xref>
###xml 1170 1177 1168 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060100-t001">Table 1</xref>
###xml 1186 1188 1184 1186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 1403 1411 1401 1409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g006">Figure 6</xref>
###xml 1417 1418 1415 1416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g006">6</xref>
###xml 1512 1520 1510 1518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060100-g006">Figure 6</xref>
###xml 293 308 <span type="species:ncbi:10090">transgenic mice</span>
###xml 440 444 <span type="species:ncbi:10090">mice</span>
###xml 531 535 <span type="species:ncbi:10090">mice</span>
###xml 677 681 <span type="species:ncbi:10090">mice</span>
###xml 796 800 <span type="species:ncbi:10090">mice</span>
###xml 991 995 <span type="species:ncbi:10090">mice</span>
###xml 1377 1381 <span type="species:ncbi:10090">mice</span>
###xml 1452 1456 <span type="species:ncbi:10090">mice</span>
Having established that the absence of glycans at the second glycosylation site of host PrP can influence PrP deposition and incubation period, albeit in a strain-dependent manner, we next investigated the importance of the first glycosylation site of PrP. This was achieved by inoculating G1 transgenic mice (that lack the ability to attach carbohydrates to the first glycosylation site of PrP; i.e., N180) with 79A or ME7 TSE strains. G1 mice had an extended incubation time when infected with 79A (+ 46 d) compared to wild-type mice (Table 1) and a prominent difference in distribution and degree of vacuolar pathology (Figure 3D). Brains of terminally ill, 79A-infected G1 mice showed mono- and unglycosylated PrPSc compared to di-, mono-, and unglycosylated PrPSc present in control 129/Ola mice (Figure 1F). Immunohistochemical analysis revealed widespread PrP deposition in both G1/79A and Wt/79A brain (Figure 6A, 6C, and 6E). However, in striking contrast to infection with 79A, G1 mice inoculated with ME7 appeared resistant to infection, remaining healthy up to 600 days post-inoculation, whereas wild-type controls had an incubation period of 163 +/- 2.0 d (Table 1). No PrPSc was found by Western blot analysis in G1 brains inoculated with ME7 (unpublished data). Moreover, pathologic studies did not show PrP deposition or spongiform degeneration in brains of G1 mice inoculated with ME7 (Figure 6B and 6D) in sharp contrast to wild-type mice that showed wide spread PrP accumulation in the brain (Figure 6F). These results again indicate that TSE strains differ dramatically in their requirements for host PrP glycosylation.
###end p 60
###begin title 61
###xml 46 50 <span type="species:ncbi:10090">Mice</span>
Immunohistochemical Analysis of Brain from G1 Mice Inoculated with TSE Strains 79A and ME7
###end title 61
###begin p 62
###xml 258 262 <span type="species:ncbi:10090">mice</span>
###xml 404 408 <span type="species:ncbi:10090">mice</span>
###xml 507 512 <span type="species:ncbi:10090">mouse</span>
###xml 612 617 <span type="species:ncbi:10090">mouse</span>
Brain sections were immunostained for PrP using monoclonal antibody 6H4 and analysed by light microscopy using a Nikon Eclipse E 800 microscope. Widespread PrP immunopositivity is seen mostly in the thalamus (A and C) of clinically positive, symptomatic, G1 mice inoculated with 79A, absence of PrP-immunopositivity in the hippocampus (B) and thalamus (D) of clinically (Clin) negative, asymptomatic, G1 mice inoculated with ME7, (E) widespread PrP deposition in the thalamus and hippocampus of a wild-type mouse (129/Ola) after inoculation with 79A; (F) widespread PrP deposition in the thalamus of a wild-type mouse with neurological signs after inoculation with ME7.
###end p 62
###begin p 63
Magnifications: (A), (B), (E), and (F), 4x; (C) and (D), 10x.
###end p 63
###begin title 64
Discussion
###end title 64
###begin p 65
###xml 438 439 438 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b003">3</xref>
###xml 859 863 859 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1003 1004 1003 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b003">3</xref>
###xml 1244 1246 1244 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b014">14</xref>
###xml 1503 1505 1503 1505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b017">17</xref>
###xml 97 101 <span type="species:ncbi:10090">Mice</span>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
###xml 357 372 <span type="species:ncbi:10090">transgenic mice</span>
###xml 603 608 <span type="species:ncbi:10090">mouse</span>
###xml 683 688 <span type="species:ncbi:10090">mouse</span>
###xml 741 745 <span type="species:ncbi:10090">mice</span>
###xml 933 948 <span type="species:ncbi:10090">transgenic mice</span>
We have demonstrated in vivo that glycosylation of host PrP is not necessary to establish a TSE. Mice expressing only unglycosylated PrP (G3 mice) are capable of supporting a TSE, albeit in a strain-dependant manner, but disease susceptibility is reduced in response to the lack of glycans on host PrP. This differs from a previous study that reported that transgenic mice expressing unglycosylated PrP were resistant to two TSE strains [3]. There are, however, considerable differences between these two studies that may account for the discrepancy including: (i) the expression of hamster rather than mouse PrP genes, (ii) different TSE strains, and (iii) the method of transgenic mouse production. Gene targeting was used to generate the mice described in this study, thus the altered PrP gene is in the normal chromosomal location and under the PrP gene (Prnp) control elements. Whereas a previous study by De Armond et al. used transgenic mice generated by random integration of the PrP transgene [3], which can result in disruption of genes at the site of integration, ectopic expression due to the influence of surrounding control elements, as well as high levels of transgene expression, all of which may affect the outcome of disease [14]. Indeed PrP glycosylation mutant transgenic lines produced by random integration and expressing the same transgene have been reported to display different incubation periods with the same TSE strain, preventing direct comparisons between different lines [17].
###end p 65
###begin p 66
###xml 562 564 562 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 718 720 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b013">13</xref>
###xml 32 47 <span type="species:ncbi:10090">transgenic mice</span>
###xml 200 206 <span type="species:ncbi:10090">murine</span>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
Our glycosylation-deficient PrP transgenic mice have both an alteration in amino acid sequence and glycosylation. Mutation of either asparagine or threonine in the NXT glycosylation consensus site of murine PrP will prevent the attachment of glycans to asparagine. We altered asparagines at both consensus sites to threonine, and this is regarded as a conservative amino acid alteration. The PrP expressed in our G1 and G2 transgenic lines is localised primarily at the cell surface in a manner comparable to that in wild-type mice and displays no detectable PrPSc-like properties as determined by PK sensitivity, cleavability by phosphatidylinositol-specific phospholipase C (PIPLC), and detergent solubility assays [13]. Moreover, remarkable similarity in the course of infection in parts of this study argues against the substituted amino acids affecting the course of disease but rather that the differences observed can be attributed to differences in glycosylation.
###end p 66
###begin p 67
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b013">13</xref>
###xml 406 407 406 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b017">17</xref>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b018">18</xref>
###xml 556 558 556 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 652 654 652 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 668 669 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 701 702 701 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 709 711 709 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 827 829 827 829 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 884 886 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b019">19</xref>
###xml 887 889 887 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b020">20</xref>
###xml 943 944 943 944 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 951 953 951 953 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 1121 1123 1121 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b021">21</xref>
###xml 1124 1126 1124 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b025">25</xref>
###xml 1279 1280 1279 1280 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 24 28 <span type="species:ncbi:10090">mice</span>
###xml 1214 1218 <span type="species:ncbi:10090">mice</span>
###xml 1490 1494 <span type="species:ncbi:10090">mice</span>
The observation that G3 mice are capable of supporting TSE disease is surprising given that the cellular location of the unglycosylated PrP appears primarily intracellular [13]. This suggests that TSE disease can occur with perhaps complete absence or at least very low levels of PrP on the cell surface. 79A may be able to infect the cell via a mechanism independent of cell surface expression of host PrPC, suggesting that transit of normal PrP to the surface of the cell [17,18] may not be an absolute requirement for the development of TSE disease. PrPSc accumulation in the TSE infected animal is considered to occur through the interaction of PrPSc with host PrPC, resulting in conversion of PrPC to PrPSc. We have established that glycosylation of host PrP is not a requirement for the formation of de novo-generated PrPSc in vivo, which is in agreement with in vitro studies [19,20]. However, there is still uncertainty as to where PrPC to PrPSc conversion occurs, with differing reports that it takes place either at the cell surface, extracellularly, in microsomes, along endocytic pathways, or in the cytosol [21-25]. In our studies, the primarily intracellular location of the unglycosylated PrP in G3 mice suggests that either the very low levels of cell surface PrPC expression is adequate to allow the conversion process to occur, or that conversion does not occur at the cell surface; in vitro studies will be necessary to resolve where conversion actually occurs in the G3 mice.
###end p 67
###begin p 68
###xml 77 79 77 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 201 203 201 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 286 288 286 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 311 313 311 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 415 417 415 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b026">26</xref>
###xml 565 567 565 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b027">27</xref>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b028">28</xref>
###xml 692 694 692 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 823 825 823 825 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 881 883 881 883 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 918 920 918 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b029">29</xref>
###xml 921 923 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b031">31</xref>
###xml 959 961 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b012">12</xref>
###xml 962 964 962 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b032">32</xref>
###xml 150 154 <span type="species:ncbi:10090">mice</span>
We have shown for the first time, to our knowledge, that glycosylation of PrPSc is not necessary for the transmission of TSE infectivity to wild-type mice. This study also revealed that the de novo PrPSc generated in the recipient animals consisted of di-, mono-, and unglycosylated PrPSc, whereas the donor PrPSc was fully unglycosylated. This is perhaps surprising, considering it is postulated that the donor PrPSc acts as a template for its amplification [26], yet our results suggest that the host dictates the glyscoylation status of the de novo-generated PrPSc, rather than that of the donor as it has also been suggested in some in vitro experiments [27,28]. The effect of host on PrPSc glycosylation should therefore be considered when glycoform analysis, which determines the ratio of di- and monoglycosylated PrPSc, as well as the relative mobility of unglycosylated PrPSc, is used to identify TSE strains [29-31] and classify newly emerging ones [12,32].
###end p 68
###begin p 69
###xml 148 149 148 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 370 371 370 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b013">13</xref>
###xml 564 565 564 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 772 773 772 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 268 272 <span type="species:ncbi:10090">mice</span>
###xml 389 393 <span type="species:ncbi:10090">mice</span>
###xml 440 444 <span type="species:ncbi:10090">mice</span>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
###xml 684 688 <span type="species:ncbi:10090">mice</span>
In contrast to the results obtained using 79A, we found that ME7 was unable to cause clinical TSE disease in mice expressing only unglycosylated PrPC. G1 mice (which have glycans only at N196) appear also resistant to TSE disease following ME7 inoculation, whereas G2 mice are fully susceptible to TSE disease with this strain. The fact that the cellular location of PrPC in the G1 and G2 mice are comparable to each other and to wild-type mice [13] indicates that the inability of ME7 to cause TSE disease in the G1 mice is not due to the cellular location of PrPC but rather due to the absence of glycans at N180. Therefore, the inability of ME7 to cause clinical TSE disease in G3 mice may also be due to lack of carbohydrates at N180, rather than the low levels of PrPC expressed at the cell surface.
###end p 69
###begin p 70
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b013">13</xref>
###xml 590 591 590 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 3 7 <span type="species:ncbi:10090">mice</span>
###xml 144 148 <span type="species:ncbi:10090">mice</span>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 314 318 <span type="species:ncbi:10090">mice</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 992 996 <span type="species:ncbi:10090">mice</span>
###xml 1232 1236 <span type="species:ncbi:10090">mice</span>
G1 mice were found to be fully susceptible to TSE disease following 79A inoculation, but with a prolonged incubation time compared to wild-type mice. Similarly, the absence of glycans at N196 resulted in a prolongation of incubation period in 79A-inoculated G2 mice. With the cellular location of PrP in G1 and G2 mice being comparable to that in wild-type mice [13], perhaps the prolongation of incubation period is due to the lack of glycans at N180 or N196, respectively, but whether this is due to a reduced efficiency of uptake, inefficient interaction of the infectious agent with PrPC due to the lack of glycans at either site, or a slightly reduced efficiency of the disease process once the infectious agent has gained access to cells can not be determined from these studies. Experiments are underway to address this issue. In contrast to the observation that the lack of glycans at N196 has little or no effect on TSE disease resulting from inoculation with 79A or ME7, not all G2 mice inoculated with the TSE strain 301C showed clinical signs of TSE disease, and furthermore, those that did had a dramatic extension of the incubation period. However, clinical TSE disease was observed in the majority of 301C-inoculated mice, despite the increase in incubation period, which indicates that this strain does not have an absolute requirement for glycans at N196 but that the presence of them does allow for a more efficient infection.
###end p 70
###begin p 71
###xml 44 48 <span type="species:ncbi:10090">mice</span>
###xml 125 129 <span type="species:ncbi:10090">mice</span>
###xml 144 148 <span type="species:ncbi:10090">mice</span>
Despite differences in susceptibility of G2 mice to infection with three different strains, the vacuolation profile of these mice and wild-type mice was similar, suggesting that glycosylation at the G2 site did not influence the strain targeting. Contrastingly, the 79A vacuolation profile in G1 was different when compared to wild type, indicating that glycosylation at the G1 site may have an effect on strain targeting. This finding will be further investigated in future experiments.
###end p 71
###begin p 72
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b033">33</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b034">34</xref>
###xml 1001 1003 1001 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b035">35</xref>
###xml 21 25 <span type="species:ncbi:10090">mice</span>
###xml 562 566 <span type="species:ncbi:10090">mice</span>
###xml 672 676 <span type="species:ncbi:10090">mice</span>
###xml 891 896 <span type="species:ncbi:10090">mouse</span>
###xml 1079 1083 <span type="species:ncbi:10090">mice</span>
###xml 1202 1217 <span type="species:ncbi:10090">transgenic mice</span>
Clinical negative G3 mice infected with 79A or ME7 have shown the presence of PrP amyloid plaques in the brain. The formation of amyloid plaques is commonly associated with the pathological process of TSE disease as well as other neurodegenerative diseases [33]. However an alternative view is that plaque formation may actually be a mechanism that the host uses to attempt to protect itself from the potentially harmful effects of oligomers [34]. If this is the case in the TSE diseases, then the lack of clinical disease in the majority of the 79A-infected G3 mice (despite the presence of TSE infectivity as demonstrated by the transmission of TSE disease to wild-type mice) could indicate that the host is attempting to protect itself from the de novo generated abnormal PrP by sequestering it as amyloid. Interestingly, PrP-amyloid plaques have been detected previously in a transgenic mouse model expressing mutant PrP in the absence of clinical signs, spongiform degeneration, and infectivity [35]. Thus a possible explanation for presence of plaques in clinical negative mice may be that amyloid formation can somehow block the propagation of disease within the brain. Our glycosylation mutant transgenic mice may therefore provide a model to investigate the involvement of PrP glycosylation on plaque formation in response to different TSE strains.
###end p 72
###begin p 73
###xml 161 163 161 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 320 322 320 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
In conclusion, we have demonstrated that glycosylation of host PrP is not essential for the host to be susceptible to TSE disease. Moreover, glycosylation of PrPSc is not necessary for the transmission of TSE infectivity to a new host, and the glycotype of the host PrP has a major influence on the de novo generated PrPSc. Finally, we have shown that host PrP has a major role to play in TSE disease susceptibility and incubation period and that TSE strains differ dramatically in their requirements for host PrP glycosylation in order to allow TSE disease to occur.
###end p 73
###begin title 74
Materials and Methods
###end title 74
###begin title 75
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
Transgenic mouse lines.
###end title 75
###begin p 76
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b013">13</xref>
###xml 32 37 <span type="species:ncbi:10090">mouse</span>
###xml 175 190 <span type="species:ncbi:10090">transgenic mice</span>
Inbred gene targeted transgenic mouse lines G1, G2, and G3, and the corresponding inbred 129/Ola wild-type control line have been described previously [13]. All gene-targeted transgenic mice used in this study were homozygous.
###end p 76
###begin title 77
###xml 14 19 <span type="species:ncbi:10090">mouse</span>
Genotyping of mouse tail DNA.
###end title 77
###begin p 78
###xml 534 536 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b013">13</xref>
###xml 52 57 <span type="species:ncbi:10090">mouse</span>
A portion of tail was removed post-mortem from each mouse. DNA was prepared from a 1-cm piece of tail by digestion overnight at 37 degreesC in tail lysis buffer (300 mM sodium acetate, 1% SDS, 10 mM Tris pH 8, 1 mM EDTA, 200 mug/ml PK) and subsequent extraction with an equal volume of phenol/chloroform. DNA was precipitated with isopropanol, washed with 70% ethanol, and re-suspended in 100 mul of TE buffer (10 mM Tris, 1 mM EDTA pH 7.4). The mismatch PCR method to identify the different transgenics has been described elsewhere [13].
###end p 78
###begin title 79
Preparation of inoculum and injection.
###end title 79
###begin p 80
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 192 196 <span type="species:ncbi:10090">mice</span>
###xml 419 423 <span type="species:ncbi:10090">mice</span>
###xml 503 508 <span type="species:ncbi:10090">mouse</span>
###xml 674 678 <span type="species:ncbi:10090">mice</span>
###xml 780 784 <span type="species:ncbi:10090">mice</span>
Inocula were prepared from the brains of C57BL mice with terminal ME7, 79A, or 301C TSE disease. A 1% homogenate of each sample was prepared in sterile saline prior to use as an inoculum. All mice were genotyped by PCR, grouped, and coded prior to intracerebral inoculation with 20 mul of inoculum under anaesthesia. For second passage experiments, separate inocula were prepared from the brains of two G2/79A infected mice with terminal TSE disease as well as from the brain of one 129/Ola (wild-type) mouse with terminal 79A scrapie as control. A 1% homogenate of each sample was prepared in sterile saline prior to use as an inoculum for inoculation of 129/Ola wild-type mice. All experimental protocols were submitted to the Local Ethical Review Committee for approval before mice were inoculated. All experiments were performed under license and in accordance with the UK Home Office Regulations (Animals (Scientific Procedures) Act 1986).
###end p 80
###begin title 81
Scoring of clinical TSE disease.
###end title 81
###begin p 82
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b016">16</xref>
###xml 162 167 <span type="species:ncbi:10090">mouse</span>
###xml 375 379 <span type="species:ncbi:10090">Mice</span>
The presence of clinical TSE disease was assessed as described previously [16]. Animals were scored for clinical disease without reference to the genotype of the mouse. Genotypes were confirmed for each animal by PCR analysis of tail DNA at the end of the experiment. Incubation times were calculated as the interval between inoculation and cull due to terminal TSE disease. Mice were killed by cervical dislocation at the terminal stage of disease, at termination of the experiment (between 500-700 d), or for welfare reasons due to intercurrent illness.
###end p 82
###begin title 83
Lesion profiles.
###end title 83
###begin p 84
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060100-b016">16</xref>
Sections were haematoxylin and eosin stained and scored for vacuolar degeneration on a scale of 0 to 5 in nine standard gray matter areas and a scale of 0 to 3 in three standard white matter areas as described previously [16].
###end p 84
###begin title 85
Immunohistochemistry.
###end title 85
###begin p 86
###xml 283 289 <span type="species:ncbi:9986">rabbit</span>
###xml 690 695 <span type="species:ncbi:10090">mouse</span>
Sections were stained for disease associated PrP using monoclonal antibody 6H4 (1/10000; Prionics). Antigen retrieval by autoclaving at 121 degreesC for 15 min, and 5 min formic acid (98%) treatment was used to facilitate the detection of PrP. Sections were then blocked with normal rabbit serum prior to incubation with the primary antibody. Antibody binding was detected with the Catalyzed Signal Amplification System (Dakocytomation) and visualized with diaminobenzidine (DAB). In all the experiments, normal brain homogenate-infected and PrP-null negative controls were used. Images were taken using a Nikon Eclipse E800 microscope. Sections were analysed by an observer blinded to the mouse genotype and type of inoculum.
###end p 86
###begin title 87
Thioflavin-S treatment.
###end title 87
###begin p 88
Brain sections were stained with haematoxylin for 30 s and then washed in water. Sections were treated with a thioflavin-s solution (10 mg/ml) for 5 min and then with a 70% ethanol solution for 5 min. After washes with water, sections were mounted using Fluorescent Mounting Medium (Dakocytomation) and analysed using a Nikon Eclipse E400 microscope with a FITC filter.
###end p 88
###begin title 89
Western blotting.
###end title 89
###begin p 90
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice were killed by cervical dislocation and brains and spleens were removed, flash frozen in liquid nitrogen, and then stored at -70 degreesC until required. Half or whole brains were weighed and mechanically homogenized from frozen in nine volumes of ice cold NP40 lysis buffer (1% Nonidet 40, 0.5% sodium deoxycholate, 150 mM NaCl, 50 mM Tris pH 7.5), with the addition of phenylmethysufonyl fluoride (PMSF) (final concentration 1muM; Sigma) to prevent protein degradation by endogenous proteases. The homogenate was centrifuged at 8000 revolutions per minute for 10 min to remove unhomogenised debris. Total protein was denatured in 1x Novex Tris-Glycine SDS Sample Buffer (Invitrogen Life Technologies) and 1x NuPage Sample Reducing Agent (Invitrogen Life Technologies) for 30 min at 95 degreesC. Proteins were separated by gel electrophoresis at 125 V using Novex Pre-cast Tris-Glycine gel (12% or 14% acrylamide, Trisglycine; Invitrogen Life Technologies). Proteins in the acrylamide gel were transferred to polyvinylindene fluoride (PVDF) membrane at 25 V (125 A/gel) using a semi-dry transfer blotter (Bio-Rad) in 1X Transfer Solution (48 mM Tris, 39 mM Glycine, 0.375 % sodium dodecyl sulphate (SDS), 20% methanol).
###end p 90
###begin p 91
###xml 372 376 <span type="species:ncbi:10090">mice</span>
We are grateful to Professor M. Bruce for critical reading of the manuscript and to Dr. J. Fraser for valuable discussions concerning this work; F. Wiseman and E. Scholefield for assistance in genotype analysis; A. Boyle and W. G. Liu for lesion profile analysis; and V. Thompson, E. Murdoch, L. Frame, and K. Hogan for the breeding, care, and the clinical scoring of the mice. This work was undertaken when the Neuropathogenesis Unit was part of the Institute for Animal Health. The findings and conclusions in this article have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency determination or policy.
###end p 91
###begin title 92
Abbreviations
###end title 92
###begin p 93
###xml 0 6 <span type="species:ncbi:9913">bovine</span>
bovine spongiform encephalopathy
###end p 93
###begin p 94
intracerebrally
###end p 94
###begin p 95
proteinase K
###end p 95
###begin p 96
prion protein
###end p 96
###begin p 97
transmissible spongiform encephalopathy
###end p 97
###begin title 98
References
###end title 98
###begin article-title 99
PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology
###end article-title 99
###begin article-title 100
Prions
###end article-title 100
###begin article-title 101
Selective neuronal targeting in prion disease
###end article-title 101
###begin article-title 102
Biochemical typing of scrapie strains
###end article-title 102
###begin article-title 103
Eight prion strains have PrP(Sc)molecules with different conformations
###end article-title 103
###begin article-title 104
PrPc glycoform heterogeneity as a function of brain region: implications for selective targeting of neuronsby prion strains
###end article-title 104
###begin article-title 105
###xml 58 64 <span type="species:ncbi:10090">murine</span>
Site-specific characterization of the N-linked glycans of murine prion protein by high-performance liquid chromatography electrospray mass spectrometry and exoglycosidase digestions
###end article-title 105
###begin article-title 106
Prion glycoprotein: structure, dynamics, and roles for the sugars
###end article-title 106
###begin article-title 107
Molecular analysis of prion strain variation and the etiology of new variant CJD
###end article-title 107
###begin article-title 108
Molecular-basis of phenotypic variability in sporadic Creutzfeldt-Jakob-disease
###end article-title 108
###begin article-title 109
###xml 54 60 <span type="species:ncbi:9606">humans</span>
Chronic wasting disease and potential transmission to humans
###end article-title 109
###begin article-title 110
###xml 27 33 <span type="species:ncbi:9913">bovine</span>
Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease
###end article-title 110
###begin article-title 111
Altered glycosylated PrP proteins can have different neuronal trafficking in brain but do not acquire scrapie-like properties
###end article-title 111
###begin article-title 112
Transgenic models of the transmissible spongiform encephalopathies
###end article-title 112
###begin article-title 113
Transmissible spongiform encephalopathy strain, PrP genotype and brain region all affect the degree of glycosylation of PrPSc
###end article-title 113
###begin article-title 114
Distribution of experimentally induced scrapie lesions in the brain
###end article-title 114
###begin article-title 115
###xml 128 134 <span type="species:ncbi:9913">bovine</span>
Glycosylation deficiency at either one of the two glycan attachment sites of cellular prion protein preserves susceptibility to bovine spongiform encephalopathy and scrapie infections
###end article-title 115
###begin article-title 116
Intracellular rerouting of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease
###end article-title 116
###begin article-title 117
Acquisition of protease resistance by prion proteins in scrapi-infected cells does not require asparagine linked glycosylation
###end article-title 117
###begin article-title 118
Expression of unglycosylated mutated prion protein facilitates PrP(Sc) formation in neuroblastoma cells infected with different prion strains
###end article-title 118
###begin article-title 119
N-terminal truncation of the scrapie associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state
###end article-title 119
###begin article-title 120
###xml 37 43 <span type="species:ncbi:10090">murine</span>
In vivo toxicity of prion protein in murine scrapie: ultrastructural and immunogold studies
###end article-title 120
###begin article-title 121
###xml 110 112 110 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sub>
Conversion of raft associated prion protein to the protease-resistant state requires insertion of PrP-res (PrPSc) into contiguous membranes
###end article-title 121
###begin article-title 122
Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol
###end article-title 122
###begin article-title 123
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse-adapted scrapie infection of SN56 cells: greater efficiency with microsome-associated versus purified PrP-res
###end article-title 123
###begin article-title 124
Non-genetic propagation of strain-specific properties of scrapie prion protein
###end article-title 124
###begin article-title 125
Molecular basis of scrapie strain glycoform variation
###end article-title 125
###begin article-title 126
The stoichiometry of host PrPC glycoforms modulates the efficiency of PrPSc formation in vitro
###end article-title 126
###begin article-title 127
Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob disease: UK cases 1991-2002
###end article-title 127
###begin article-title 128
Coexistence of multiple PrPSc types in individuals with Creutzfeldt-Jakob disease
###end article-title 128
###begin article-title 129
Detection of type 1 prion protein in variant Creutzfeldt-Jakob disease
###end article-title 129
###begin article-title 130
###xml 39 44 <span type="species:ncbi:9940">sheep</span>
###xml 82 88 <span type="species:ncbi:9913">bovine</span>
###xml 145 150 <span type="species:ncbi:9940">sheep</span>
Molecular analysis of cases of Italian sheep scrapie and comparison with cases of bovine spongiform encephalopathy (BSE) and experimental BSE in sheep
###end article-title 130
###begin article-title 131
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
###end article-title 131
###begin article-title 132
The most infectious prion protein particles
###end article-title 132
###begin article-title 133
Accumulation of prion protein in the brain that is not associated with transmissible disease
###end article-title 133
###begin p 134
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. NLT, EC, HB, and JCM conceived and designed the experiments. NLT, EC, HB, LB, BB, CP, AC, and PH performed the experiments. NLT, EC, PP, and JCM analyzed the data. RB contributed reagents/materials/analysis tools. NLT, EC, and JCM wrote the paper.
###end p 134
###begin p 135
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. This study was supported by the Biotechnology and Biological Sciences Research Council and the Medical Research Council.
###end p 135
###begin p 136
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 136

